Compare Estee Lauder Companies Inc (EL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs GSK plc — how do they compare? Estee Lauder Companies Inc trades at $98.05 (market cap $34.17B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 2.7× Estee Lauder Companies Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and GSK plc for 93 Days on average.
| EL | GSK | |
|---|---|---|
Market Cap | $34.17B | $91.88B |
Volume | 3,921,497 | 7,730,529 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $61.18 |
52-Week Low | $67.23 | $43.24 |
Typical Hold Time | 122 Days | 93 Days |
Enterprise Value | $39.92B | $111.88B |
Dividend Yield | 1.48% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $94.32, down 0.14% on the day, with a neutral technical signal. The stock has beaten earnings estimates for the last three quarters, though annual revenue declined to $14.33B in 2025 with a net loss of $1.13B. Analyst consensus is a Buy with a $103.00 price target, and recent news highlights strategic partnerships in AI and leadership appointments aimed at strengthening brand strategy.
The outlook is cautiously optimistic, supported by earnings beats and positive analyst sentiment, but risks include sustained profitability challenges, high debt levels, and competitive pressures. Upside potential exists if margin improvements and strategic initiatives translate to earnings growth, yet investors must monitor execution on turnaround efforts.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
